Ceftazidime/avibactam is a combination of beta-lactam/beta-lactamases inhibitor, which 13 use is restricted to some clinical cases including cystic fibrosis patients infected with 14 multidrug resistant Pseudomonas aeruginosa, in which mutation is the main driver of 15 resistance. This study aims to predict the mechanisms of mutation-driven resistance that 16 are selected for when P. aeruginosa is challenged with either ceftazidime or 17 ceftazidime/avibactam. For this purpose, P. aeruginosa PA14 was submitted to 18 experimental evolution in the absence of antibiotics and in the presence of increasing 19 concentrations of ceftazidime or ceftazidime/avibactam for 30 consecutive days. Final 20 populations were analysed by whole-genome sequencing. All evolved populations 21 reached similar levels of ceftazidime resistance. Besides, all of them were more 22 susceptible to amikacin and produced pyomelanin. A first event in the evolution was the 23 selection of large chromosomal deletions containing hmgA (involved in pyomelanin 24 production), galU (involved in β-lactams resistance) and mexXY-oprM (involved in 25 aminoglycoside resistance). Besides mutations in mpl and dacB that regulate β-26 lactamase expression, mutations related to MexAB-OprM overexpression were 27 prevalent. Ceftazidime/avibactam challenge selected mutants in the putative efflux 28 pump PA14_45890-45910 and in a two-component system (PA14_45870-45880), likely 29 regulating its expression. All populations produce pyomelanin and were more 30 susceptible to aminoglycosides likely due to the selection of large chromosomal 31 deletions. Since pyomelanin-producing mutants, presenting similar deletions are 32 regularly isolated from infections, the potential aminoglycosides hyper-susceptiblity and 33 reduced β-lactams susceptibility of pyomelanin-producing P. aeruginosa should be 34 taken into consideration for treating infections by these isolates. 35 42 including those encoding multidrug (MDR) efflux pumps (4) and beta-lactamases. In 43 addition, an increasing number of P. aeruginosa isolates has acquired several resistance 44 genes through horizontal gene transfer (HGT), including different classes of 45
INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen widely distributed in nature (1), 37 which is a major cause of lung and airway infections in hospitalized patients, as well as 38 chronic infections in patients with cystic fibrosis (CF) and chronic obstructive 39 pulmonary disease (2, 3) . This bacterial species presents a characteristic low 40 susceptibility to antibiotics, including β-lactams, which is mainly the consequence of its 41 low permeability and the presence in its genome of different intrinsic resistance genes, acquire high-level ceftazidime resistance. An increase in the MIC of an antibiotic after 138 experimental evolution does not necessarily imply that antibiotic-resistant mutants have 139 been selected for: resistance may have arisen due to a phenotypic (inducible) adaptation 140 to the presence of ceftazidime rather than to mutations (19) (20) (21) . To address this 141 possibility, the evolved populations were cultured in the absence of selection pressure 142 (three sequential passages on LB) and the MICs again determined. These were found 143 not to vary, indicating that the observed modifications were due to the selection of 144 stable mutants.
145
Cross-resistance and collateral sensitivity of the evolved populations 146 Taking into consideration the few therapeutic options for patients submitted to 147 ceftazidime/avibactam therapy, knowing whether or not acquisition of resistance to this 148 combination might alter the susceptibility to other antibiotics is of crucial importance. 149 To that end, the susceptibility to a range of representative antibiotics was tested by disk 150 diffusion assay (Table S4 ). From these results, a set of antibiotics was chosen for 151 determining their MICs against the different evolved populations. Every evolved 152 replicate showed altered susceptibility to antimicrobials belonging to different structural 153 families ( Table 1) , implying that at least some resistance mutations were not 154 ceftazidime-or ceftazidime/avibactam-specific. All populations evolved in the presence 155 of either ceftazidime or ceftazidime/avibactam presented decreased susceptibility to 156 other β-lactams, to chloramphenicol and to erythromycin and they were more 157 susceptible to fosfomycin and to amikacin. Notably, while populations evolving in the 158 presence of ceftazidime were less susceptible to tetracycline and did not present changes 159 in the susceptibility to tigecycline, populations evolved in the presence of 160 ceftazidime/avibactam were hyper-susceptible to both antibiotics.
161
Analysis of mutations associated with the acquisition of resistance 162 To know the genetic events associated with the acquisition of resistance in the evolved 163 populations, the genomes of each, as well as that of the original PA14 strain, were 164 sequenced on the last day of the experiment. Table 2 encompasses the resulting mutated   165 genes and their functional significance, whereas Table S1 shows the locations of all 40 166 genetic changes that were unveiled and were not present in control populations evolving 167 in the absence of antibiotics. A total of 37 single nucleotide variants (SNVs) and 3 168 multi-nucleotide variants (MNVs; deletions and substitutions of various nucleotides) 169 were found, 36 located in genes and 4 in intergenic regions. Most mutations located in 170 genes resulted in amino acid alterations, stop codons or frameshifts. In addition, all the 171 populations evolved in the presence of antibiotics contained large chromosomal 172 deletions (55 to 443 kbp) representing from 0,88% to 7,09% of the P. aeruginosa PA14 173 genome. Five different deletions were selected, they all presenting a 55 kbp common 174 region ( Figure 3 ).
To verify the presence and the order of appearance of the genetic changes identified by 176 WGS, the regions holding these mutations were amplified using specific 177 oligonucleotides (Table S2 ) and the amplicons Sanger-sequenced in each evolutionary 178 step ( Figure 4 ). Regarding the large chromosomal deletions, primers located at the 179 flanking sequences were used to verify their presence. In all cases, these analyses 180 confirmed the information obtained from WGS. with antibiotic produced a brown pigment, which appeared to be pyomelanin, whose 185 accumulation is normally due to the lack of homogentisate 1,2-dioxygenase activity 186 provided by the enzyme HmgA (22). All the chromosomal large deletions selected 187 during evolution presented hmgA (Figure 3 ). In addition, the deletions included as well 188 galU (involved in LPS biosynthesis), whose inactivation reduces ceftazidime 189 susceptibility (23); and the MDR efflux pump mexXY-oprM, which contributes to 190 aminoglycoside resistance in P. aeruginosa (24). Deletion of the latter is likely the 191 cause of the observed amikacin hyper-susceptibility of all evolved populations (Table   192 1).
193
Another common element in both evolutions is nalD, which encodes a secondary 194 repressor of 26) . Three out of eight replicates showed the same 195 T11N change, which has been previously found in XDR P. aeruginosa high-risk clones 196 (27) that overexpress MexAB-OprM. Notably, four replicates (including the three 197 presenting mutations in nalD) also presented mutations in mexB, indicating this efflux 198 system to be a relevant element in the acquisition of resistance. Two other elements that 199 are selected for in both treatments are ftsI and clpA. The first encodes PBP3, the target 200 of different β-lactams (28, 29), which has been already found to be mutated in 201 numerous resistant P. aeruginosa isolates. Indeed, the mutations R504C/H found in 202 populations 1 and 5 are also present among isolates from widespread 203 nosocomial P. aeruginosa clones (29-31). clpA encodes for an intracellular protease 204 involved in different aspects of P. aeruginosa physiology, in addition to aztreonam 205 resistance (28, 32).
206

Mutations selected by ceftazidime 207
In addition to the observed mutations in nalD, which would allow mexAB-oprM 208 overexpression, we found as well mutations that should lead to the overexpression of 209 this system in the populations evolving under ceftazidime challenge. Two populations 210 carried mutants in mexR, which encodes a local repressor of mexAB-oprM expression.
211
Another population presented a mutation upstream mexA that might prevent the 212 interaction of NalD with its operator (25), thus allowing mexAB-oprM overexpression.
213
Other mutations specifically selected for by ceftazidime were found in mpl and dacB. 214 The proteins encoded by these genes are involved in the recycling of peptidoglycan 215 muropeptides. Besides, they control the activity of AmpR and consequently the level of 216 AmpC expression (23, 33), which is known to be a main element in P. aeruginosa 217 resistance to β-lactams. Interestingly, mpl V124G (replicate 2, Table S1) has been found 218 before in a clinical isolate (P. aeruginosa NCGM1984). These finding, along with the 219 ftsI and nalD mutations aforementioned, validate our experimental evolution approach 220 as a valuable predictive model for the in vivo selection of antibiotic resistance.
221
Finally, mutations at orfN, pitA, infB, grpE, clpP and dnaK were selected for in 222 populations challenged with ceftazidime. orfN codes for a putative glycosyl transferase 223 of type A flagellins (34). Mutations on this gene have been found in ciprofloxacin P. shown this efflux pump to be involved in P. aeruginosa intrinsic resistance (37) and 236 susceptibility to carbapenems (38). Regarding the substrate recognition profile this 237 pump might display, it is remarkable that populations 5 and 7, which present the 238 aforementioned mutations, show a much lower susceptibility to imipenem than any 239 other replicate (Table 1 ), suggesting this pump to have certain specificity to 240 carbapenems.
241
Other mutations that were selected upon ceftazidime/avibactam treatment were found in 242 pepA, spoT, dnaJ and flgF. pepA encodes for a protease necessary for P. aeruginosa 243 cytotoxicity, virulence and, consequently, lung infection (39, 40) . Although its 244 implication in antibiotic resistance has not been studied in detail, it has been reported 245 that its inactivation confers meropenem resistance in P. aeruginosa (41). Moreover, 246 pepA mutants are selected in the presence of aztreonam (28). SpoT has been related to 247 piperacillin resistance (42); while DnaJ, a chaperone protein and FlgF, a flagellar basal 248 body rod protein (43), have been reported to modify the susceptibility of E. coli to a 249 range of antibiotics when they are inactivated (36).
250
The other mutations that were selected for in populations under ceftazidime/avibactam 251 challenge; namely those occurring in ctpA, an essential gene for the transition between 252 acute and chronic P. aeruginosa infection (44), pcm, that encodes for a L-isoaspartate 253 carboxylmethyltransferase type II that participates in protein repair and degradation and 254 glnD, which is implicated in N2 metabolism, (45) have not been reported to be involved 255 in antibiotic resistance. 
322
Although most of the mutants here reported have been previously associated to be 323 involved in antibiotic resistance, it is still possible that some of the mutations might be 324 selected for compensating the fitness costs associated with the acquisition of resistance.
325
This might be the case of ctpA, pcm or the mutations at structural elements of efflux 326 pumps that were selected after mutations in the regulators of their expression. For the 327 latter, it might also be possible that these mutations increase the capability of extruding 328 the antibiotic substrates, as described for AcrB (61). The fact that in all evolved 329 populations mutants in efflux pumps are selected, provides an explanation of the cross-330 resistance phenotype observed in all resistant strains. This situation might be of 331 concern, since both ceftazidime and ceftazidime/avibactam might select for resistance to 332 other antibiotics, at least along chronic infections in which mutation is the main cause of 333 acquisition of resistance. However, this evolution provides a link between antibiotic resistance and virulence for 339 this relevant pathogen. In any case, and given that deletions containing galU and hmgA 340 appear to be a first step on the evolution towards ceftazidime/avibactam resistance, pyomelanin production could be considered as a marker in the selection of the antibiotic 342 of choice for treating P. aeruginosa infections. Both in vitro work, including the results 343 here shown, and the analysis of clinical pyomelanin-producers, have shown that these 344 isolates are hyper-susceptible to aminoglycosides probably because the deletions they 345 present include mexXY. It would then be judicious using aminoglycosides, and not β- The table shows previously described effects in the susceptibility to antibiotics of mutations in the genes that appear to be mutated in the 561 experimental evolution. mexR mutation in ceftazidime population 2 actually indicates that this mutation 597 occurred in the intergenic region between mexR and mexA. The "*" refers to a second 598 mutation in a gene that mutated before. We cannot ditch that other mutations may have 599 appeared over the 30 days evolution process. "Δ": large deletion. Rep: replicate. Black The table presents the diameters of halo (mm) in the disk diffusion assays for each replicate population at the end of the experimental 630 evolution. The antibiotics in which halos differed were selected for an E-test assay (Table 1) . Indeed, in some cases we chose for the E-test 631 only one or two representative cases of a particular structural family, in order to avoid redundancy. Double inhibition halos are shown as 632 two values separated by a slash (X/X 13  12  0  19  0  0  30  21  26  26  26  29  32  19  15  0  0  27  2  15  12  0  19  0  0  33  26  28  29  29  31  35  19  16  0  0  33  3  15  10  0  25  0  0  31  24  28  25  24  28  32  19  16  0  0  27  4  15  12  0  22  0  0  33  24  28  27  28  31  36  19  16  0  0  31  CEFTAZIDIME + AVIBACTAM  5  19  19  0  10  0  0  33  30  31  24  23  28  31  17  15  0  6  27  6  20  22  7  24  0  0  34  30  33  25  22  29  34  18  16  0  0  26  7  23  22  0  9  0  0  38  32  34  23  22  26  33  19  16  0  0  25  8  21  19  0  24  0  0  33  29  28  26  24  30  34  19  16  0  0  27 
